| HCPCS J9274 | Injection, tebentafusp-tebn, 1 microgram | Current code | 28 hospitals |
|---|
| HCPCS J9276 | Injection, zanidatamab-hrii, 2 mg | Current code | 25 hospitals |
|---|
| HCPCS J9280 | Injection, mitomycin, 5 mg | Current code | 44 hospitals |
|---|
| HCPCS J9281 | Mitomycin pyelocalyceal instillation, 1 mg | Current code | 29 hospitals |
|---|
| HCPCS J9285 | Injection, olaratumab, 10 mg | Current code | 34 hospitals |
|---|
| HCPCS J9286 | Injection, glofitamab-gxbm, 2.5 mg | Current code | 35 hospitals |
|---|
| HCPCS J9289 | Injection, nivolumab, 2 mg and hyaluronidase-nvhy | Current code | 27 hospitals |
|---|
| HCPCS J9292 | Injection, pemetrexed dipotassium, 10 mg | Current code | 21 hospitals |
|---|
| HCPCS J9293 | Injection, mitoxantrone hydrochloride, per 5 mg | Current code | 41 hospitals |
|---|
| HCPCS J9294 | Injection, pemetrexed (hospira), not therapeutically equivalent to j9305, 10 mg | Current code | 28 hospitals |
|---|
| HCPCS J9295 | Injection, necitumumab, 1 mg | Current code | 35 hospitals |
|---|
| HCPCS J9296 | Injection, pemetrexed (accord), not therapeutically equivalent to j9305, 10 mg | Current code | 35 hospitals |
|---|
| HCPCS J9297 | Injection, pemetrexed (sandoz), not therapeutically equivalent to j9305, 10 mg | Current code | 27 hospitals |
|---|
| HCPCS J9298 | Injection, nivolumab and relatlimab-rmbw, 3 mg/1 mg | Current code | 39 hospitals |
|---|
| HCPCS J9299 | Injection, nivolumab, 1 mg | Current code | 43 hospitals |
|---|
| HCPCS J9300 | Injection, gemtuzumab ozogamicin, 5 mg | Retired code | 1 hospital |
|---|
| HCPCS J9301 | Injection, obinutuzumab, 10 mg | Current code | 43 hospitals |
|---|
| HCPCS J9302 | Injection, ofatumumab, 10 mg | Current code | 35 hospitals |
|---|
| HCPCS J9303 | Injection, panitumumab, 10 mg | Current code | 42 hospitals |
|---|
| HCPCS J9304 | Injection, pemetrexed (pemfexy), 10 mg | Current code | 28 hospitals |
|---|
| HCPCS J9305 | Injection, pemetrexed, not otherwise specified, 10 mg | Current code | 41 hospitals |
|---|
| HCPCS J9306 | Injection, pertuzumab, 1 mg | Current code | 42 hospitals |
|---|
| HCPCS J9307 | Injection, pralatrexate, 1 mg | Current code | 40 hospitals |
|---|
| HCPCS J9308 | Injection, ramucirumab, 5 mg | Current code | 40 hospitals |
|---|
| HCPCS J9309 | Injection, polatuzumab vedotin-piiq, 1 mg | Current code | 35 hospitals |
|---|
| HCPCS J9310 | Injection, rituximab, 100 mg | Retired code | 1 hospital |
|---|
| HCPCS J9311 | Injection, rituximab 10 mg and hyaluronidase | Current code | 30 hospitals |
|---|
| HCPCS J9312 | Injection, rituximab, 10 mg | Current code | 45 hospitals |
|---|
| HCPCS J9313 | Injection, moxetumomab pasudotox-tdfk, 0.01 mg | Current code | 28 hospitals |
|---|
| HCPCS J9314 | Injection, pemetrexed (teva), not therapeutically equivalent to j9305, 10 mg | Current code | 28 hospitals |
|---|
| HCPCS J9315 | Injection, romidepsin, 1 mg | Retired code | 20 hospitals |
|---|
| HCPCS J9316 | Injection, pertuzumab, trastuzumab, and hyaluronidase-zzxf, per 10 mg | Current code | 35 hospitals |
|---|
| HCPCS J9317 | Injection, sacituzumab govitecan-hziy, 2.5 mg | Current code | 42 hospitals |
|---|
| HCPCS J9318 | Injection, romidepsin, non-lyophilized, 0.1 mg | Current code | 28 hospitals |
|---|
| HCPCS J9319 | Injection, romidepsin, lyophilized, 0.1 mg | Current code | 40 hospitals |
|---|
| HCPCS J9320 | Injection, streptozocin, 1 gram | Current code | 34 hospitals |
|---|
| HCPCS J9321 | Injection, epcoritamab-bysp, 0.16 mg | Current code | 35 hospitals |
|---|
| HCPCS J9322 | Injection, pemetrexed (bluepoint), not therapeutically equivalent to j9305, 10 mg | Current code | 22 hospitals |
|---|
| HCPCS J9323 | Injection, pemetrexed ditromethamine, 10 mg | Current code | 28 hospitals |
|---|
| HCPCS J9324 | Injection, pemetrexed (pemrydi rtu), 10 mg | Current code | 28 hospitals |
|---|
| HCPCS J9325 | Injection, talimogene laherparepvec, per 1 million plaque forming units | Current code | 35 hospitals |
|---|
| HCPCS J9328 | Injection, temozolomide, 1 mg | Current code | 36 hospitals |
|---|
| HCPCS J9329 | Injection, tislelizumab-jsgr, 1mg | Current code | 26 hospitals |
|---|
| HCPCS J9330 | Injection, temsirolimus, 1 mg | Current code | 41 hospitals |
|---|
| HCPCS J9340 | Injection, thiotepa, 15 mg | Retired code | 25 hospitals |
|---|
| HCPCS J9342 | Injection, thiotepa, not otherwise specified, 1 mg | Current code | 30 hospitals |
|---|
| HCPCS J9345 | Injection, retifanlimab-dlwr, 1 mg | Current code | 28 hospitals |
|---|
| HCPCS J9347 | Injection, tremelimumab-actl, 1 mg | Current code | 35 hospitals |
|---|
| HCPCS J9348 | Injection, naxitamab-gqgk, 1 mg | Current code | 29 hospitals |
|---|
| HCPCS J9349 | Injection, tafasitamab-cxix, 2 mg | Current code | 29 hospitals |
|---|
| HCPCS J9350 | Injection, mosunetuzumab-axgb, 1 mg | Current code | 35 hospitals |
|---|
| HCPCS J9351 | Injection, topotecan, 0.1 mg | Current code | 33 hospitals |
|---|
| HCPCS J9352 | Injection, trabectedin, 0.1 mg | Current code | 41 hospitals |
|---|
| HCPCS J9353 | Injection, margetuximab-cmkb, 5 mg | Current code | 40 hospitals |
|---|
| HCPCS J9354 | Injection, ado-trastuzumab emtansine, 1 mg | Current code | 35 hospitals |
|---|
| HCPCS J9355 | Injection, trastuzumab, excludes biosimilar, 10 mg | Current code | 42 hospitals |
|---|
| HCPCS J9356 | Injection, trastuzumab, 10 mg and hyaluronidase-oysk | Current code | 33 hospitals |
|---|
| HCPCS J9357 | Injection, valrubicin, intravesical, 200 mg | Current code | 37 hospitals |
|---|
| HCPCS J9358 | Injection, fam-trastuzumab deruxtecan-nxki, 1 mg | Current code | 43 hospitals |
|---|
| HCPCS J9359 | Injection, loncastuximab tesirine-lpyl, 0.075 mg | Current code | 35 hospitals |
|---|
| HCPCS J9360 | Injection, vinblastine sulfate, 1 mg | Current code | 37 hospitals |
|---|
| HCPCS J9370 | Vincristine sulfate, 1 mg | Current code | 38 hospitals |
|---|
| HCPCS J9371 | Injection, vincristine sulfate liposome, 1 mg | Retired code | 25 hospitals |
|---|
| HCPCS J9380 | Injection, teclistamab-cqyv, 0.5 mg | Current code | 37 hospitals |
|---|
| HCPCS J9382 | Injection, zenocutuzumab-zbco, 1 mg | Current code | 16 hospitals |
|---|
| HCPCS J9390 | Injection, vinorelbine tartrate, 10 mg | Current code | 34 hospitals |
|---|
| HCPCS J9393 | Injection, fulvestrant (teva), not therapeutically equivalent to j9395, 25 mg | Current code | 28 hospitals |
|---|
| HCPCS J9394 | Injection, fulvestrant (fresenius kabi) not therapeutically equivalent to j9395, 25 mg | Current code | 33 hospitals |
|---|
| HCPCS J9395 | Injection, fulvestrant, 25 mg | Current code | 41 hospitals |
|---|
| HCPCS J9400 | Injection, ziv-aflibercept, 1 mg | Current code | 35 hospitals |
|---|
| HCPCS J9600 | Injection, porfimer sodium, 75 mg | Current code | 27 hospitals |
|---|
| HCPCS J9999 | Not otherwise classified, antineoplastic drugs | Current code | 7 hospitals |
|---|
| HCPCS Q2017 | Injection, teniposide, 50 mg | Retired code | 24 hospitals |
|---|
| HCPCS Q2040 | Tisagenlecleucel, up to 250 million car-positive viable t cells, including leukapheresis and dose preparation procedures, per infusion | Retired code | 2 hospitals |
|---|
| HCPCS Q2041 | Axicabtagene ciloleucel, up to 200 million autologous anti-cd19 car positive viable t cells, including leukapheresis and dose preparation procedures, per therapeutic dose | Current code | 25 hospitals |
|---|
| HCPCS Q2042 | Tisagenlecleucel, up to 600 million car-positive viable t cells, including leukapheresis and dose preparation procedures, per therapeutic dose | Current code | 17 hospitals |
|---|
| HCPCS Q2043 | Sipuleucel-t, minimum of 50 million autologous cd54+ cells activated with pap-gm-csf, including leukapheresis and all other preparatory procedures, per infusion | Current code | 28 hospitals |
|---|
| HCPCS Q2049 | Injection, doxorubicin hydrochloride, liposomal, imported lipodox, 10 mg | Current code | 28 hospitals |
|---|
| HCPCS Q2050 | Injection, doxorubicin hydrochloride, liposomal, not otherwise specified, 10 mg | Current code | 43 hospitals |
|---|
| HCPCS Q2053 | Brexucabtagene autoleucel, up to 200 million autologous anti-cd19 car positive viable t cells, including leukapheresis and dose preparation procedures, per therapeutic dose | Current code | 26 hospitals |
|---|
| HCPCS Q2054 | Lisocabtagene maraleucel, up to 110 million autologous anti-cd19 car-positive viable t cells, including leukapheresis and dose preparation procedures, per therapeutic dose | Current code | 21 hospitals |
|---|
| HCPCS Q2057 | Afamitresgene autoleucel, including leukapheresis and dose preparation procedures, per therapeutic dose | Current code | 15 hospitals |
|---|
| HCPCS Q2058 | Obecabtagene autoleucel, 10 up to 400 million cd19 car-positive viable t cells, including leukapheresis and dose preparation procedures, per infusion | Current code | 15 hospitals |
|---|
| HCPCS Q5107 | Injection, bevacizumab-awwb, biosimilar, (mvasi), 10 mg | Current code | 43 hospitals |
|---|
| HCPCS Q5112 | Injection, trastuzumab-dttb, biosimilar, (ontruzant), 10 mg | Current code | 33 hospitals |
|---|
| HCPCS Q5113 | Injection, trastuzumab-pkrb, biosimilar, (herzuma), 10 mg | Current code | 28 hospitals |
|---|
| HCPCS Q5114 | Injection, trastuzumab-dkst, biosimilar, (ogivri), 10 mg | Current code | 33 hospitals |
|---|
| HCPCS Q5116 | Injection, trastuzumab-qyyp, biosimilar, (trazimera), 10 mg | Current code | 42 hospitals |
|---|
| HCPCS Q5117 | Injection, trastuzumab-anns, biosimilar, (kanjinti), 10 mg | Current code | 35 hospitals |
|---|
| HCPCS Q5118 | Injection, bevacizumab-bvzr, biosimilar, (zirabev), 10 mg | Current code | 41 hospitals |
|---|
| HCPCS Q5123 | Injection, rituximab-arrx, biosimilar, (riabni), 10 mg | Current code | 43 hospitals |
|---|
| HCPCS Q5126 | Injection, bevacizumab-maly, biosimilar, (alymsys), 10 mg | Current code | 35 hospitals |
|---|
| HCPCS Q5129 | Injection, bevacizumab-adcd (vegzelma), biosimilar, 10 mg | Current code | 33 hospitals |
|---|
| HCPCS Q5146 | Injection, trastuzumab-strf (hercessi), biosimilar, 10 mg | Current code | 19 hospitals |
|---|
| HCPCS Q5157 | Injection, denosumab-bmwo (stoboclo/osenvelt), biosimilar, 1 mg | Current code | 13 hospitals |
|---|
| HCPCS Q5158 | Injection, denosumab-bnht (bomyntra/conexxence), biosimilar, 1 mg | Current code | 13 hospitals |
|---|